Final Clinical Takeaways on ADC Use

The final takeaways emphasize that antibody drug conjugates are becoming an increasingly important part of gynecologic cancer care, but their successful use depends on staying current with rapidly evolving data and recognizing that these agents are not interchangeable. Faculty stress that drugs with similar overall activity may carry very different toxicity profiles, and those differences have direct implications for patient counseling, supportive care, and treatment sequencing. Another major message is the importance of thinking beyond the immediate next line of therapy, since payload choice today may influence trial eligibility and later options tomorrow. Experience from other disease settings can also be valuable, particularly when it helps clinicians anticipate and manage toxicities before they become treatment limiting. Clinical trial participation remains essential because many of the most important questions about resistance, sequencing, duration of therapy, and optimal combinations remain unanswered. The overall conclusion is that antibody drug conjugates have opened meaningful new possibilities, but better evidence and careful clinical judgment will determine how fully those possibilities translate into improved patient care.